In refractory CAPS associated with active SLE, in addition to CYC or rituximab, hydroxychloroquine would decrease platelet activation, reduce attachment of the aPL-β2GP1 complex to the membrane, and decrease thrombotic and cardiovascular risk [82]. The gene discussed is FASLG; the disease is systemic lupus erythematosus.